Patents Examined by Maria Osoteo
  • New cyclic FR-900520 microbial biotransformation agent
    Patent number: 5290689
    Abstract: Described is a process for producing a new immunosuppressant, a C-19/C-22 cyclic hemiketal (Compound I) biotransformation analog of FR-900520, under novel fermentation conditions utilizing the novel microorganism, Streptomyces sp. (Merck Culture Collection MA6969) ATCC No. 55280. The macrolide immunosuppressant is useful in preventing human host rejection of foreign organ transplants, e.g. bone marrow, liver, lung, kidney and heart transplants.
    Type: Grant
    Filed: September 28, 1992
    Date of Patent: March 1, 1994
    Assignee: Merck & Co., Inc.
    Inventors: George M. Garrity, Magda M. Gagliardi, Shieh-Shung T. Chen
  • Cyclic FR-900520 microbial biotransformation agent
    Patent number: 5283183
    Abstract: Described is a process for producing a new immunosuppressant, a C-19/C-22 cyclic hemiketal (Compound I) biotransformation analog of FR-900520, under novel fermentation conditions utilizing the novel microorganism, Streptomyces sp. (Merck Culture Collection MA6971) ATCC No. 55282. The macrolide immunosuppressant is useful in preventing human host rejection of foreign organ transplants, e.g. bone marrow, liver, lung, kidney and heart transplants.
    Type: Grant
    Filed: September 28, 1992
    Date of Patent: February 1, 1994
    Assignee: Merck & Co., Inc.
    Inventors: George M. Garrity, Shieh-Shung T. Chen
  • Biological process for enhanced manganese and silver recovery from refractory manganiferous silver ore
    Patent number: 5283192
    Abstract: Disclosed is an efficient biological process for recovering silver and manganese from refractory manganiferous silver ore. The process utilizes manganese reducing Bacillus sp. Specifically exemplified is a novel microbe designated Bacillus MBX 69, or mutants thereol Further, gene(s) encoding the enzyme(s) obtainable from the said bacteria can be used by placing such gene(s) on a suitable vector and transforming a competent host. The transformed host then can be used to recover silver and manganese from refractory manganiferous silver ore.
    Type: Grant
    Filed: December 9, 1992
    Date of Patent: February 1, 1994
    Assignee: Metallurgical and Biological Extraction Systems, Inc.
    Inventor: Patricia A. Rusin
  • Cyclic FR-900520 microbial biotransformation agent
    Patent number: 5268282
    Abstract: Described is a process for producing a new immunosuppressant, a C-19/C-22 cyclic hemiketal (Compound I) biotransformation analog of FR-900520, under novel fermentation conditions utilizing the novel microorganism, Streptomyces sp. (Merck Culture Collection MA6970) ATCC No. 55281. The macrolide immunosuppressant is useful in preventing human host rejection of foreign organ transplants, e.g. bone marrow, liver, lung, kidney and heart transplants.
    Type: Grant
    Filed: September 28, 1992
    Date of Patent: December 7, 1993
    Assignee: Merck & Co., Inc.
    Inventors: George M. Garrity, Shieh-Shung T. Chen
  • Cyclic FR-900520 microbial biotransformation agent
    Patent number: 5268281
    Abstract: Described is a process for producing a new immunosuppressant, a C-19/C-22 cyclic hemiketal (Compound I) biotransformation analog of FR-900520, under novel fermentation conditions utilizing the novel microorganism, Streptomyces sp. (Merck Culture Collection MA6968) ATCC No. 55279. The macrolide immunosuppressant is useful in preventing human host rejection of foreign organ transplants, e.g. bone marrow, liver, lung, kidney and heart transplants.
    Type: Grant
    Filed: September 28, 1992
    Date of Patent: December 7, 1993
    Assignee: Merck & Co., Inc.
    Inventors: George M. Garrity, Magda M. Gagliardi, Shieh-Shung T. Chen